Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immuron.
RELATED STOCKHEAD STORIES
News
CLOSING BELL: It’s never a good idea to let the ASX dress all in red ‘just like Santa Claus’
News
ASX Small Caps Lunch Wrap: Whose bright idea was it to have such a horribly sad day?
Investor Guides
Investor Guide: Health & Biotech FY2023
News
Trading Places: BGH ups Virtus stake to above 50pc as battle for fertility company escalates
Health & Biotech
Check Up: Money managers are still bullish on Healthcare; here’s what they said
Health & Biotech
Check Up: Immuron wins big in US and Europe on travellers’ diarrhoea drug
News
Closing Bell: ASX bounces back as US markets prepare for the inflation genie
Health & Biotech
ASX Health Stocks: Immuron up 29pc on $6.2m travellers’ diarrhoea clinical study for US military
Health & Biotech
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech
ASX Health Stocks: Mesoblast jumps 10pc on Phase 3 trial results for chronic heart failure
News
Closing Bell: ASX gains to close out the week as US default fears ease
News
10 at 10: These ASX stocks are undergoing rapid growth this morning
News
Last Orders: What you might have missed on the ASX today
News
Closing Bell: Today’s biggest small cap movers on the ASX
News
ASX stocks in America: Opthea’s about to join the ranks but who’s there already?
Health & Biotech
The 6 ASX small cap biotechs that have more than doubled in 2020
Health & Biotech